- Home
- » Tags
- » Gangliosidosis
Top View
- Insilico Analysis Reveal Three Novel Nssnps May Effect on GM2A Protein Leading to AB Variant of GM2 Gangliosidosis
- Three Mutations That Cause Fifferent Forms of Canine Neuronal Ceroid Lipofuscinosis
- Lipid Storage Diseases
- GM1 Gangliosidosis: Review of Clinical, Molecular, and Therapeutic Aspects
- Synaptic Dysfunction As a Starting Point for Disease Progression
- Abnormal Sphingolipid World in Inflammation Specific for Lysosomal
- Concentrations of an Activator Protein for Sphingolipid Hydrolysis in Liver and Brain Samples from Patients with Lysosomal Storage Diseases
- Immunological Evidence for Deficiency in an Activator Protein for Sulfatide
- GM2 Gangliosidosis AB Variant
- Lysosomal Storage Diseases ª the Author(S) 2014 DOI: 10.1177/2326409813517663 Iem.Sagepub.Com
- Chemical Chaperone Therapy for Brain Pathology in GM1-Gangliosidosis
- Sphingolipidoses
- Allelic Variation at the HUYA, HEXB, and GM2A Gene Loci Paulo Cordeiro, MSC',Peter Hechtmatl, P~D'-~,Ard Feige Kaplan, ~Hd-7'
- I-Cell Disease-Mucolipidosis II NEIL GORDON M.D., F.R.C.P
- GM2 Gangliosidosis: Clinical Features and Current Therapies
- Lysosomal Lipid Storage Diseases
- 2012-01 Matreya Newsletter.Pub
- Calling GM1, GM2 Tay-Sachs and Sandhoff, and Canavan Families... A